Natixis Advisors LLC Makes New $1.62 Million Investment in Astrana Health, Inc. (NASDAQ:ASTH)

Natixis Advisors LLC bought a new stake in Astrana Health, Inc. (NASDAQ:ASTH) in the 3rd quarter, HoldingsChannel reports. The institutional investor bought 27,980 shares of the company’s stock, valued at approximately $1,621,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. GAMMA Investing LLC purchased a new position in Astrana Health in the third quarter worth $34,000. Nisa Investment Advisors LLC purchased a new position in shares of Astrana Health in the 3rd quarter worth about $35,000. KBC Group NV purchased a new stake in Astrana Health during the third quarter worth about $70,000. Central Pacific Bank Trust Division bought a new stake in Astrana Health in the third quarter worth about $160,000. Finally, Everence Capital Management Inc. purchased a new position in Astrana Health in the third quarter valued at about $272,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on ASTH. BTIG Research upped their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Truist Financial increased their price target on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Robert W. Baird boosted their price objective on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. TD Cowen started coverage on shares of Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 target price for the company. Finally, Stifel Nicolaus boosted their price target on shares of Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Astrana Health currently has an average rating of “Buy” and an average price target of $65.17.

Astrana Health Stock Up 0.7 %

Shares of NASDAQ ASTH opened at $42.40 on Tuesday. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The company has a market cap of $2.39 billion, a P/E ratio of 32.92, a P/E/G ratio of 1.95 and a beta of 1.24. Astrana Health, Inc. has a 52 week low of $32.32 and a 52 week high of $63.20. The business has a 50-day simple moving average of $54.17 and a two-hundred day simple moving average of $47.94.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period last year, the business earned $0.47 earnings per share. Research analysts anticipate that Astrana Health, Inc. will post 1.17 earnings per share for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.